Back to top
more

Phibro Animal Health (PAHC)

(Real Time Quote from BATS)

$26.62 USD

26.62
67,767

-0.52 (-1.92%)

Updated Aug 5, 2025 02:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Insulet Gains 62.9% in a Year: What's Driving the Stock?

by Zacks Equity Research

PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.

Zacks Equity Research

Should You Consider Retaining ZBH Stock in Your Portfolio Now?

by Zacks Equity Research

Zimmer Biomet's robust Knee business appears promising. However, a dull macroeconomic condition adds to the worry.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here's Why You Should Retain AMED Stock in Your Portfolio Now

by Zacks Equity Research

Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.

Zacks Equity Research

Is it Apt to Retain HAE Stock in Your Portfolio for Now?

by Zacks Equity Research

Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.

Zacks Equity Research

Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?

by Zacks Equity Research

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

Zacks Equity Research

PAHC vs. BSX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Phibro Animal Health (PAHC) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?

by Zacks Equity Research

Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.

Zacks Equity Research

Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?

by Zacks Equity Research

QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.

Zacks Equity Research

Boston Scientific Gains 42.2% in a Year: What's Driving the Stock?

by Zacks Equity Research

BSX's shares rise on the back of its innovative product portfolio and impressive value-added acquisition. However, the unfavorable macroeconomic scenario is concerning.

Zacks Equity Research

Reasons to Hold TNDM Stock in Your Portfolio for Now

by Zacks Equity Research

A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.

Zacks Equity Research

Phibro Animal Health Stock Up 87.5% in a Year: What's Driving the Rise?

by Zacks Equity Research

PAHC stays on investors' radar due to its Animal Health business and potential in emerging markets.

Zacks Equity Research

Why Is Phibro (PAHC) Down 5.2% Since Last Earnings Report?

by Zacks Equity Research

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is it Worth Adding ResMed Stock to Your Portfolio Now?

by Zacks Equity Research

Robust Mask and Device sales bode well for ResMed. Meanwhile, the increasing debt burden adds to the worry.

Zacks Equity Research

Reasons to Retain Envista Stock in Your Portfolio for Now

by Zacks Equity Research

NVST's impressive long-term growth initiatives appear promising. Yet, a leveraged balance sheet is worrisome.

Zacks Equity Research

Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Growing Thrombectomy Business Supports PEN Stock, Macro Issues Ail

by Zacks Equity Research

Penumbra is still in the early stages of its journey to bring the company's proprietary thrombectomy technologies to patients in the United States and around internationally.

Zacks Equity Research

Alcon Stock Gains From Innovation Despite Macroeconomic Troubles

by Zacks Equity Research

Within Vision Care, ALC is registering solid growth, banking on strong sales of its contact lenses and ocular health products.

Zacks Equity Research

Is it Apt to Retain Omnicell Stock in Your Portfolio Now?

by Zacks Equity Research

OMCL stays on investors' radar due to its impressive long-term growth initiative.

Zacks Equity Research

Is PAHC Stock a Smart Addition to Your Portfolio Right Now?

by Zacks Equity Research

Phibro's robust performance in the Animal Health business and prospects in the emerging markets are highly encouraging.

Zacks Equity Research

Zacks.com featured highlights Brinker, AppLovin and Phibro Animal Health

by Zacks Equity Research

Brinker, AppLovin and Phibro Animal Health have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Strong Buy Stocks for the Momentum Investor

by Tirthankar Chakraborty

Brinker International, AppLovin and Phibro Animal Health have been selected as the momentum picks for the day using the Driehaus strategy.

Zacks Equity Research

3 Reasons Why Growth Investors Shouldn't Overlook Phibro (PAHC)

by Zacks Equity Research

Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

PAHC or SYK: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PAHC vs. SYK: Which Stock Is the Better Value Option?